CVKD Cadrenal Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1937993 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.8%
TTM EPS YoY57.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-358.3%
ROA-267.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets16.0%
Debt / equity0.00x
Current ratio6.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20082008-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| Cost of revenue | — | — | $220,095 | — | $220,095 |
| R&D expense | $4.10M | $4.21M | $4.08M | $392,859 | $200,000 |
| SG&A expense | $9.35M | $6.75M | $3.55M | $2.31M | — |
| Operating income | -$13.46M | -$10.96M | -$7.63M | -$2.70M | — |
| Interest expense | — | — | $3,534 | $40,192 | — |
| Pretax income | -$13.24M | -$10.65M | -$8.36M | -$6.71M | — |
| Net income | -$13.24M | -$10.65M | -$8.36M | -$6.71M | — |
| EBITDA | -$13.45M | -$10.96M | -$7.63M | -$2.70M | — |
| EPS (basic) | -6.64 | -8.73 | -9.29 | -0.85 | — |
| EPS (diluted) | -6.64 | -8.73 | -9.29 | -0.85 | — |
| Dividends declared per share | 16.50 | 16.50 | — | — | — |
| Weighted avg. shares (diluted) | 1.99M | 1.22M | 899,465 | 7.89M | — |
| Balance sheet | |||||
| Cash & equivalents | $4.01M | $10.02M | $8.40M | $32,586 | — |
| Current assets | $4.32M | $10.11M | $8.49M | $727,596 | — |
| PP&E, net | $5,174 | $6,944 | $2,287 | $1,013 | — |
| Total assets | $4.33M | $10.12M | $8.52M | $778,174 | — |
| Current liabilities | $1.59M | $2.68M | $826,875 | $1.33M | — |
| Short-term debt | — | — | — | $597,068 | — |
| Total liabilities | $1.59M | $2.68M | $826,875 | $6.33M | — |
| Shareholders' equity | $2.74M | $7.44M | $7.69M | -$5.55M | — |
| Shares outstanding | 2.34M | 1.78M | 868,184 | 8.19M | — |
| Cash flow statement | |||||
| Operating cash flow | -$12.60M | -$7.36M | -$3.53M | -$1.20M | — |
| Capital expenditure | $5,104 | $6,537 | $3,254 | $2,279 | — |
| Free cash flow | -$12.61M | -$7.36M | -$3.53M | -$1.21M | — |
| Investing cash flow | -$5,104 | -$6,537 | -$3,254 | -$2,279 | — |
| Financing cash flow | $6.60M | $8.98M | $11.90M | $1.24M | — |
| Depreciation & amortization | $6,874 | $1,880 | $1,980 | $1,266 | — |
| Stock-based compensation | $1.94M | $1.42M | $710,381 | $928,049 | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.